Libtayo wins conditional approval in Europe

1 July 2019
sanofi-big-1

Libtayo (cemiplimab) has been granted conditional approval for the treatment of certain adults with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC), one of the most commonly diagnosed skin cancers worldwide.

The decision makes the product, which is being jointly developed by Sanofi (Euronext: SAN) and Regeneron (Nasdaq: REGN), the only approved checkpoint inhibitor in advanced CSCC in Europe. Libtayo was approved in the USA last September.

Updated results from the registrational EMPOWER-CSCC-1 trial were recently shared at the 2019 annual meeting of the American Society of Clinical Oncology annual meeting.

Investigator Axel Hauschild said: “With no other medical treatments approved for advanced CSCC in the EU, Libtayo represents an important new option for patients affected with this advanced skin cancer who cannot be cured by surgery or radiation.”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology